Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy
PLOS One · 30.03.2026 · 21 (3) · e0343704
DOI: 10.1371/journal.pone.0343704 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 30.03.2026. Verfasst von Jae Ryong Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Central Serous Chorioretinopathy, Adrenal Cortex Hormones, Triamcinolone Acetonide. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Ministry of Trade, Industry & Energy, the Ministry of Health & Welfare.
Abstract (Originalsprache)
Central serous chorioretinopathy (CSC) is strongly associated with systemic corticosteroid use, but the risk following intravitreal steroid injections remains unclear, with limited evidence from isolated case reports. This study evaluated the association between intravitreal steroid injections and CSC development using a dual-approach design with Clinical Data Warehouse (CDW) analysis and choroidal thickness validation. We performed CDW analysis of 2,336 patients receiving intravitreal triamcinolone acetonide or dexamethasone implant over 21 years (April 2003–October 2024), screening for CSC within 6 months post-injection. Additionally, we conducted detailed subfoveal choroidal thickness analysis in 269 eyes (January 2023–October 2024) at baseline, 1, 3, and 6 months post-injection using optical coherence tomography. No confirmed CSC cases occurred in either cohort (0/2,336 patients, 95% CI: 0–0.13%; 0/269 eyes). Contrary to the choroidal thickening characteristic of CSC, both steroid formulations produced significant choroidal thinning at 1 month: dexamethasone implant (227.0 ± 65.4μm to 217.9 ± 62.0μm, p < 0.0001) and triamcinolone acetonide (219.8 ± 78.7μm to 218.6 ± 77.7μm, p < 0.0001). Only 4.9% of eyes showed ≥10% choroidal thickening, and none developed CSC features. Both formulations achieved significant macular edema reduction through 6 months. Intravitreal corticosteroids showed no confirmed CSC cases over two decades with choroidal thinning rather than the thickening characteristic of CSC, suggesting distinct pathophysiological mechanisms and a favorable safety profile regarding CSC development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
ORCID-Profile: Se Joon Woo
Förderung
- the Ministry of Trade, Industry & Energy
- the Ministry of Health & Welfare
Zitieren
APA
Song, J. R., & Woo, S. J. (2026). Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy. PLOS One, 21(3), e0343704. https://doi.org/10.1371/journal.pone.0343704
Vancouver
Song JR, Woo SJ. Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy. PLOS One. 2026;21(3):e0343704. doi:10.1371/journal.pone.0343704
BibTeX
@article{Song2026,
author = {Song, Jae Ryong and Woo, Se Joon},
title = {Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0343704},
doi = {10.1371/journal.pone.0343704}
}
EUVIMED